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Abstract.To improve the etiological diagnosis of neurodegenerative dementias like Alzheimer’s disease (AD) or frontotemporal
dementia (FTD), we evaluated the value of individual and combined measurements of the following relevant cerebrospinal fluid
(CSF) biomarkers: Tau, 181p-Tau, A38, A40, A42, sAPP, and sAPP. This study conducted in two centers included
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patients with FTD (n = 34), AD (n = 52), as well as a control group of persons without dementia (CTRL, n = 42). Identical
clinical criteria and pre-analytical conditions were used while CSF biomarkers were measured using commercial single and
multiplex quantitative immunoassays. Thorough statistical analyses, including ROC curves, logistic regressions, and decision
trees, were performed. We validated in AD the specific increase of p-Tau levels and the decrease of A42 levels, two biological
hallmarks of this disease. Tau concentrations were highest in AD and intermediate in FTD when compared to CTRL. The
most interesting results were obtained by focusing on amyloid biomarkers as we found out in FTD a significant decrease of
sAPP, A38, and A40 levels. A38 in particular was the most useful biomarker to differentiate FTD subjects from the CTRL
population. Combining p-Tau and A38 led us to correctly classifying FTD patients with sensitivity at 85% and specificity at
82%. Significant changes in amyloid biomarkers, particularly for A38, are therefore seen in FTD. This could be quite useful
for diagnosis purposes and it might provide additional evidence on the interrelationship between Tau and APP biology which
understanding is essential to progress towards optimal therapeutic and diagnostic approaches of dementia.
Keywords: Alzheimer’s disease, frontotemporal dementia, CSF biomarkers, CSF amyloid peptides, A38
INTRODUCTION
Cerebrospinal fluid (CSF) biomarkers analysis is an
important tool for the early and etiological differen-
tial diagnosis of dementia. Accurate diagnosis is now
becoming mandatory to optimize patient’s therapeutic
care, alleviate the burden of caregivers, and conduct
clinical trials. Based on the revised Alzheimer’s dis-
ease (AD) diagnosis criteria [1, 2], our routine clinical
practice now includes the dosage in the CSF of the Tau
protein, its phosphorylated form phospho-tau181 (p-
Tau) and the A peptides 1–42 (A42). The relevance
of using a combination of these three CSF biomark-
ers has been validated for the diagnosis of AD and its
prodromal forms [3–7]. However, their pertinence is
limited for the etiological diagnosis of dementia and for
related diseases like frontotemporal lobar degeneration
(FTLD) and its subtype with predominant behavioral
impairments called frontotemporal dementia (FTD).
The presence of depressive or behavioral disorders in
the early stage of the disease could in fact mislead the
clinician. In 50% of these clinical presentations, the
diagnosis happens at a late stage and remains doubt-
ful. To date, no satisfactory set of CSF biomarkers
have been thoroughly validated to discriminate FTLD
from AD and other neurological disorders. Increased
Tau levels were initially selected as specific to this
diagnosis [8, 9], but further studies showed normal
or decreased levels [10-13]. Additional discrepancies
were observed for the combined measurement or ratio
of Tau and A42 which was either not relevant [14]
or had no diagnosis usefulness [12, 15]. Recently, the
value of CSF A40 was pointed out to discriminate
FTD from control non-demented subjects [16]. How-
ever, in this same study the value of this analyte to
distinguish FTD from AD was limited.
Other CSF biomarkers like the soluble amyloid-
protein precursor (sAPP) and isoforms, as well as
additional A peptides have been identified as poten-
tially pertinent to detect AD and its prodromal states,
but also for differential AD diagnosis [17, 18]. In a
recent work, we investigated the biological relationship
between these biomarkers and underlined the strong
correlations between sAPP, A40, and A38 CSF
levels [19]. Our results suggested that in the presence
of an amyloid pathology such as AD, the various A
peptides would have different evolutions, which could
be interesting for differentiating AD from other neu-
rodegenerative disorders in particular FTD. To test this
hypothesis, we evaluated here the diagnostic signifi-
cance of individual and combined levels (ratios) of Tau,
p-Tau, sAPP/, and A38, A40, and A42 peptides
in FTD, AD, and a control population (CTRL) without
dementia. We first confirmed the usefulness of p-Tau
and A42 in AD detection. In FTD, Tau concentra-
tions were intermediate between AD and CTRL and
we observed for this diagnosis significant decreased
levels of sAPP, A38 and A40. These results were
used to optimize FTD detection using both p-Tau and
A38 levels. We also interpreted the changes of amy-
loid biomarkers in FTD as an additional evidence of
the interrelationship between Tau and APP biology,
its understanding being essential to progress towards
optimal therapeutic care and diagnostic methods for
dementia.
MATERIALS AND METHODS
Study design and subjects
A total of 128 CSF samples were collected
from patients referred to our neurological and Clin-
ical Research Memory Centers for cognitive or
behavioral disorders (Biobank officially registered
# DC-2008-417). All the patients gave their writ-
ten informed consent to participate in this research
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study. CSF dosages of Tau, p-Tau, A38, A40, and
A42 were performed for all subjects. The CSF
sAPP/ assay was only done on the 86 AD and
FTD patients. All patients underwent a standardized
clinical investigation including anamnestic, clinical,
neuropsychological, screening laboratory tests, brain
morphological (computed tomography (CT) scans,
and/or magnetic-resonance imaging (MRI)) or func-
tional (single photon emission tomography 99 m
Tc-ECD-SPECT scans (SPECT)) imaging evalua-
tions. The standardized neuropsychometric battery for
patients with cognitive alterations included the mini-
mental status examination (MMSE) [20], the MATTIS
dementia rating scale [21], the Frontal Assessment Bat-
tery [22], and the Free and Cued Recall Test [23].
AD patients met the diagnosis criteria of NIN
CDS/ADRDA [24] and the DSM IV. In these patients,
the neuropsychological tests reflected an amnesic syn-
drome with a hippocampal deficit associated to aphasia
and agnosia. The morphological and functional imag-
ing displayed global cortical atrophy or temporal and
parietotemporal atrophy, such as hypometabolism in
these regions on SPECT data.
The diagnosis assessment of patients with clinically
validated FTD included full medical history, thor-
ough neurological examination and evaluation by at
least two independent and experimented reviewers.
The diagnosis was based on the Lund and Manch-
ester criteria established in 1994 and revised by Neary
and McKhann [25]. Only patients with a full con-
sensus agreement by the experts were recruited. We
selected patients with neuropsychological tests reflect-
ing dysexecutive deficit with behavioral disorders such
as apathy, disinterest, loss of self-awareness, social
inappropriateness, and clinical frontal signs (persever-
ative behavior, grasping). We excluded patients with
language troubles (verbal fluency or semantic) such as
progressive primary aphasia (PPA) or semantic demen-
tia (SD). The morphological and functional imaging
displayed global cortical atrophy or frontal and fron-
totemporal atrophy such as hypometabolism in these
regions on the SPECT data. No predominant ante-
rior temporal lobe lesion was observed. No clinical
parkinsonism sign was underlined in these patients.
No clinical or electrophysiological sign of motoneuron
disease was observed in our FTD group of patients. To
detect familial FTD cases we relied on the algorithm for
genetic testing by Goldman et al. [26], which excluded
in most cases these forms in patients above the age of
50 and without any familial history. Furthermore, FTD
diagnosis in our population was based on a 3 to 5-year
clinical follow-up.
Various control patients (CTRL) without cognitive
impairments, memory, or behavioral complaints were
included: 14 patients with chronic hydrocephalus, 12
with peripheral neuropathy, 11 with mild depression,
and 5 with multiple sclerosis. For each diagnosis,
the criteria were validated by multidisciplinary teams.
Each clinical investigation, e.g., biological, electro-
physiological, and neuroimaging exams were also in
favor of each diagnosis included in the CTRL (e.g.,
for hydrocephalus all exams point to the diagnosis) of
course the results of the exams correspond to the raised
diagnosis.
CSF samples and assays
Lumbar puncture (LP) was performed in standard-
ized conditions preferentially between 11 : 00 and
13 : 00 to minimize diurnal variation of CSF A levels
[27]. CSF were transferred to the laboratories in less
than 4 hours, centrifuged (1000 × g, 10 min, at 4–8◦C,
without breaks), and aliquoted in polypropylene tubes
before storage at –80◦C. The three routine CSF
biomarkers were determined using standardized com-
mercially available ELISA Kits (Innotest -amyloid
1–42, hTau, and Phospho-Tau (181P), Innogenet-
ics, Ghent, Belgium). The IATI score was calculated
using the formula IATI = A42/(240 + 1.18 × Tau) as
described [5]. Detection of CSF sAPP/ and
A38, A40, and A42 was performed indepen-
dently in the two laboratories using multiplex kits
from MSD (Meso-Scale-Discovery ref: K11120E,
K11148E). Common quality controls ensured that the
inter-laboratory variability was similar to the inter-
assay variability. All reagents were provided with the
kits along with antibody precoated 96-well plates. The
detailed procedures of the assays, very similar to clas-
sical ELISA but with a final quantitation on the MSD
Sector Imager 6000 plate reader, are provided else-
where [19]. A42 peptide levels assessed with Inno-
genetics kits were identified in the text as “Inno-A42”.
Statistical analysis
Statistical analyses were performed with the soft-
ware MedCalc (7.3). Graphic results were presented
as medians and interquartile ranges (Figs. 1–3). Statis-
tical analysis of the characteristics of the three clinical
groups (Table 1) was performed with the one-way
ANOVA and the chi-2 tests. Unpaired Student’s t tests
and Mann-Whitney tests were used to evaluate the sig-
nificance of the difference between two sample groups
(Figs. 1–3). Receiver Operating Characteristic (ROC)
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Fig. 1. Box/dot plots showing median values and quartiles of individual biomarkers in AD, FTD, and CTRL populations. Non parametric
Mann-Whitney tests were used to calculate the indicated p values. The red solid squares indicated outliner values defined as values larger than
the upper quartile plus 1.5 times the interquartile range.
curves and logistic regression were used to select the
most relevant diagnosis biomarkers (see description of
the tests in Tables 2–3).
RESULTS
General characteristics of our population
As reported in Table 1, AD, FTD, and CTRL groups
did not differ in gender, CSF total protein or Aß40.
They globally differed in age (ANOVA, p = 0.003) but
the only pairwise statistical difference was between
AD and CTRL (Student’s t test, p < 0.001) and no sta-
tistical difference (p = 0.1) was observed between FTD
and CTRL patients. Moreover, there was no significant
correlation between age and any other parameters (data
not shown). The mean MMSE score was lower in the
AD than in the FTD groups (Student’s t test, p < 0.005)
while CTRL had, as expected, much higher and signif-
icantly different values (Student’s t test, p < 0.001).
Mean values of routine CSF biomarkers
Pairwise comparisons of Tau, p-Tau, Inno-A42
(Table 1 and Figs. 1A–C), and Innogenetics A/Tau
index (IATI) (Fig. 2A) were done for the three clinical
groups. Tau concentrations were the highest in the AD
group and intermediate in the FTD group when com-
pared with the CTRL population (Fig. 1A). P-Tau was
also statistically higher in AD than in CTRL or FTD
(Fig. 1B). Inno-A42 values were clearly decreased in
AD and intermediate in FTD, which was a first indica-
tion that this pathology also had an impact on amyloid
biomarkers (Fig. 1C). IATI which has been designed
to amplify the opposite variation of Tau and A42
in AD followed the same pattern as A42 (Fig. 2A).
All together, these results validated known differences
between the values of these routines biomarkers in
different clinical situations.
Mean values of amyloid CSF biomarkers
measured with multiplex assays
A42 multiplex value variations (Fig. 1F) were com-
parable to those of the Inno-A42 discussed above
(correlation, p < 0.0001). Interestingly, CSF concen-
trations of both A38 and A40 were significantly
lower in FTD than in AD or CTRL (Figs. 1D-E).
Since our CTRL population was heterogeneous, when
we restricted the comparison with FTD to “healthy”
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Fig. 2. Box/dot plots showing median values and quartiles of individual biomarkers in AD, FTD, and CTRL populations. Non parametric
Mann-Whitney tests were used to calculate the indicated p values. The red solid squares indicated outliner values defined as values larger than
the upper quartile plus 1.5 times the interquartile range.
Fig. 3. Box/dot plots showing median values and quartiles of sAPP and  in AD and FTD. Non parametric Mann-Whitney tests were used
to calculate the indicated p values.
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Table 1
Demographic and biologic characteristics
AD (n = 52) FTD (n = 34) CTRL (n = 42) Statistical test
Mean SD Mean SD Mean SD Type of test p value
Age (yrs) 68.51 9.28 64.91 10.51 59.55 16.27 Anova p = 0,003*
CSF-Prot (g/L) 0.49 0.19 0.50 0.38 0.52 0.24 Anova p = 0,870
MMSE 15.89 7.04 21.17 6.74 29.95 0.22 Anova p < 0,001*
Inno-Aß 42 (ng/L) 449 149 682 223 805 248 Anova p < 0,001*
Tau (ng/L) 755 354 317 189 238 86 Anova p < 0,001*
p-Tau (ng/L) 102 43 41 14 41 15 Anova p < 0,001*
IATI 0.46 0.39 1.22 0.48 1.59 0.55 Anova p < 0,001*
sAPP 25043 7129 22523 6032 / / Wilcoxon p = 0,1484
sAPP 39407 8813 34895 8699 / / Wilcoxon p = 0,0243*
Aß 38 (ng/L) 1278 686 942 350 1904 962 Anova p < 0,001*
Aß 40 (ng/L) 8330 4218 6612 2152 7650 2395 Anova p = 0,058
Aß 42 (ng/L) 487 282 768 378 1434 758 Anova p < 0,001*
Aß 38/42 2.95 1.23 1.47 1.01 1.55 1.17 Anova p < 0,001*
Aß 40/42 20.51 9.87 10.43 6.02 7.17 5.66 Anova p < 0,001*
Aß 40/38 7.37 2.99 7.41 1.88 4.98 2.82 Anova p < 0,001*
Sex (M/F) 26/26 20/14 20/22 Chi2 p = 0,8612
The “*” means that the result is statistically significant.
patients (i.e., with no active neurological disease), we
still obtained highly significant differences in Ab38
values (p < 0.0001, not shown).
Concentration of sAPP but not of sAPP was
also significantly higher in AD than in FTD (Figs. 3A-
B). This result was in accordance to previous works by
our team and others [18, 19], suggesting that sAPP
might be a valuable diagnosis marker of AD.
The combined measurement of the different A
peptides allowed us to calculate ratios (Table 1,
Figs. 2B-D). Both A40/42 and A38/42 ratios were
significantly altered in AD as already reported [28–30].
We also computed the ratio A40/38 that interestingly
was the only one that differentiated clearly CTRL
subjects from FTD subjects, while not being signif-
icant between AD and FTD. A few outlier samples
(see isolated dots on Figs. 1, 2), probably linked to
pre-analytical differences, analytical variation, clini-
cal phenotypical variation, or misclassifications, were
detected. However they did not significantly affect the
statistical significance of our results (e.g., in Fig. 1D,
A38 remained significantly different between AD and
FTD after removing the two AD outliners).
Receiver operating characteristic (ROC)
ROC curves were computed for each biomarker
or ratio in relevant differential diagnostic situations
(Table 2 and Fig. 4). For FTD versus AD diagnosis, the
best AUCs for amyloid biomarkers were the A38/42
ratio and the IATI (AUCs = 0.87). However, A40/42
ratio or A42 alone had very close and statistically
undifferentiated AUC values. It is interesting to note
that p-Tau outperformed all these single biomarkers or
ratios with an AUC at 0.95. A40, sAPP, sAPP,
and A40/38 ratios were also clearly less efficient for
differentiating FTD from AD.
For FTD versus CTRL, A38 and the ratio A40/38
were the best biomarkers (AUCs = 0.81). Interestingly,
these biomarkers were better than A40 (AUC = 0.63)
which was identified in a previous study while com-
paring FTD and normal controls [16].
Logistic regression analysis
To combine the diagnosis power of several biomark-
ers we performed a multiple logistic regression
analysis (Table 3). To identify FTD from AD+CTRL,
the only two variables retained in the model were p-Tau
and A38 with a couple sensitivity/specificity (Se/Sp)
56%/89% (mean 72.5%; Table 3A). This result was
relatively low validating the difficulty to differentiate
FTD. To discriminate AD vs. FTD + CTRL, only two
variables were also kept: p-Tau and the IATI with an
excellent Se/Sp = 86%/96% (mean 91%; Table 3B).
DISCUSSION
In this report, we presented the results of classical
(Tau, p-Tau181, and A42) and new CSF neurochemi-
cal biomarkers such as soluble forms of amyloid pre-
cursor proteins (sAPP, sAPP) and A peptides
(A38, A40) and their relevance in the differential
diagnosis between AD, FTD, and control patients
(CTRL) without dementia. Biological data were col-
lected in two independent laboratories using similar
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Fig. 4. Receiver Operating Characteristic (ROC) curves plot the true positive rate in function of the false positive rate at different cut-off points.
A good estimation of the value of a biomarker is given by the area under the curve (AUC) of the ROC (see also table 3) which tends to be higher
while the curve is closer to the upper left corner, where the values of the specificity and the sensitivity are the highest. ROC curves were plotted
for the different individual biomarkers (panel A and B) and their ratios (panel C and D) to discriminate FTD from AD (panel A and C) and FTD
from CTRL (panel B and D).
and controlled pre-analytic and analytic conditions
[31]. Moreover, a recent investigation on sAPPs
CSF levels already supported the specificity of the
detection assays used in the present study [18]. All
clinical diagnoses were validated independently by a
multidisciplinary and expert team blinded to all the
CSF neurochemical outcome measures. Unfortunately,
neuropathological data were not available, which rep-
resents a limitation of the study. The AD diagnosis
was however corroborated by the classical CSF pro-
file (Tau, p-Tau, A42) with higher Tau, p-Tau, and
lower A42 compared to CTRL and FTD patients.
In particular, p-Tau reached very high sensitivity (Se)
and specificity (Sp) values that outperformed the other
biomarkers. The A38/42, 40/42 and the IATI ratios
were also better than individual biomarkers to iden-
tify AD therefore justifying their clinical relevance [5,
32].
The focus of our study was the variation of CSF
neurochemical biomarkers in FTD. We first observed
that FTD Tau levels were higher than those in CTRL,
but lower than those in AD as validated by previous
reports [12, 13, 33]. CSF Tau is regarded as a marker
of both neuronal degeneration and Tau pathology in
the brain [34, 35]. FTD are, however, not always asso-
ciated to high CSF Tau in particular when linked to
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Table 2
ROC curve area for single variable, selection of the best sensitivity and specificity values1
Table 2A
FTD vs AD Tau p-Tau A 38 A 40 A 42 IATI A 38/42 A 40/42 A 40/38 sAPP sAPPß
Sensitivity 88 91 91 91 79 88 88 79 76 59 67
Specificity 82 88 40 34 62 86 86 76 44 64 71
Cut-off ≤448 ≤58 ≤1394 ≤8896 >464 >0.66 ≤2.00 ≤11.1 >6.53 ≤23335 ≤36033
AUC 0.88 0.95 0.64 0.61 0.75 0.87 0.87 0.85 0.51 0.61 0.67
Table 2B
FTD vs CTRL Tau p-Tau A 38 A 40 A 42 IATI A 38/42 A 40/42 A 40/38
Sensitivity 50 42 94 71 88 79 65 85 91
Specificity 81 74 64 57 67 57 59 69 76
Cut-off >300 >43 ≤1470 ≤7148 ≤1111 ≤1.58 ≤1.29 >5.93 >5.28
AUC 0.62 0.53 0.81 0.63 0.78 0.69 0.57 0.74 0.81
1Receiver Operating Characteristic (ROC) curve plots the true positive rate in function of the false positive rate at different cut-off points (see
Fig. 3). A good estimation of the value of a biomarker is given by the area under the curve (AUC) of the ROC (last lane of each table below).
The indicated sensitivity and specificity corresponded to the values obtained at the cut-off selected at the highest accuracy point (minimal false
negative and false positive results).
Table 3
Logistic regression2
Table 3A3
FTD vs AD + CTRL p-Tau A 38 IATI A 38/42 A 40/42 A 40/38
ROC 0.71 0.70 0.63 0.77 0.66 0.59 Sensitivity 56
Retained Yes Yes no no no no --> Specificity 89
Table 3B4
AD vs FTD + CTRL Tau p-Tau A42 IATI A38/42 A40/42
ROC 0.93 0.97 0.88 0.92 0.89 0.90 Sensitivity 86
Retained no Yes no Yes no no --> Specificity 96
2Logistic regression is a technique for analyzing problems in which there are one or more independent variables
(here the biomarkers) which determine an outcome that is measured with a dichotomous variable in which there are
only two possible outcomes (FTD or not FTD for example). Sensitivity (upper case) and specificity (lower case)
indicated in the tables for each combination were obtained by logistic regression using a backward model. The
backward method consists at entering all selected variables into the model and next removing the non-significant
variables (P > 0.1) sequentially.; 3Multiple logistic regression indicating the resulting sensitivity and specificity (left
part) for detection FTD vs AD + CTRL. The variables with significant ROC areas were selected to be considered
in the model. Variables no retained based on their resulting p values after regression (p > 0.1) were indicated on
the last lane (no or Yes).; 4Multiple logistic regression indicating the resulting sensitivity and specificity (left part)
for detection AD vs FTD + CTRL. The variables with significant ROC areas were selected to be considered in the
model. Variables no retained based on their resulting p values after regression (p > 0.1) were indicated on the last
lane (no or Yes).
Tau mutations or in specific regional forms with lobar
localization predominant on the frontal or temporal
lobe [14, 36, 37]. The correlation between CSF Tau
levels and lobe localization was recently researched
[33], showing that higher CSF Tau levels were signif-
icantly associated to a greater atrophy in the language
areas, namely the left middle temporal gyrus and left
inferior parietal lobule. Such a correlation was not the
objective of our study but an increased Tau in some
patients could be related to the regional distribution
of the pathology. In addition, FTD forms exist with-
out a defined Tau pathology [38]. In conclusion, it is
apparent that FTD regroups both clinical and biologi-
cal entities that are different but one could be mistaken
for the others. Familial FTD forms linked to mutation
are probably the easiest to regroup and were avoided in
our study. Motoneuron variant are also characterized
by specific features but here we really focused on the
behavioral variant of Fronto-Temporal Lobar Degener-
ation (FTLD) with behavioral form of frontotemporal
syndrome (FTD) with no language or semantic diffi-
culties. If total Tau in our cohort was higher in FTD
than in CTRL, p-Tau 181 levels were however similar
suggesting that we did not have a significant number
of AD patients misdiagnosed for FTD. Tau aggrega-
tion in the brain is strongly linked to Tau abnormal
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phosphorylation [34, 35], but in FTD patients, nor-
mal or sub-normal levels of p-Tau have been already
described [33, 37, 39]. This might be due to specific
histological forms [36] or to the sequestration of p-Tau
in the filamentous inclusions. This situation is similar
to pathologies like prion diseases characterized by a
high Tau/p-Tau ratio[40]. The results of the “classic”
CSF biomarkers (Tau, p-Tau181, and A42) validated
the high diagnostic value of p-Tau for AD and the
moderate changes of Tau in FTD when compared to
CTRL. A clear CSF profile of FTD that would signif-
icantly improve the diagnosis of this pathology was
nevertheless not seen with this set of biomarkers.
The focus on the CSF amyloid status of FTD
revealed an interesting new finding with a significant
decrease of A38, A40 and sAPP in this diagno-
sis (Fig.s 1D, 1E, 3B). The presence of lower CSF
A38 levels in FTD confirmed previous results using
A-SDS-PAGE/immunoblot techniques [17] or using
the same multiplex assays as in our study, but in
smaller series [39]. In fact, A38 appeared to be as
relevant as A40, a biomarker pointed out as useful in
a recent study comparing FTLD subjects and normal
controls [16]. The specific decrease of A38 in FTD
was not only a way of differentiating this diagnosis
from CTRL, it was also quite relevant when combined
to A42 to differentiate FTD from AD with an excel-
lent 88% sensitivity and 86% specificity (Table 2A).
This A38/42 ratio appeared more pertinent than A42
alone or than the A40/42 ratio as already pointed out
in a previous analysis [32].
Finally, when all biomarkers and ratios where con-
sidered to help define a specific FTD CSF profile
(Table 3), it was not surprising that both A38 and
p-Tau were selected using backward multiple logistic
regression. If we used these biomarkers sequentially
using the ROC cut-off (Table 2), starting from 128
samples, 51 could be classified as AD (above 58pg/mL
for p-Tau). Out of the 77 remaining, 31 could be classi-
fied as FTD (A38 under 1470pg/mL). Taken together,
these two simple criteria reached an 85.3% Se and
81.9% Sp for FTD diagnosis. This “decision tree” clas-
sification might be used by other laboratories with
the same detection kits and/or after adjusting cut-off
values.
The fact that amyloid biomarkers were modified in
FTLD/FTD as reported in our study and others [16, 39]
raised many questions on the relationship between Tau
and amyloid biology. The effect of A on Tau phospho-
rylation [41] has been demonstrated in different models
[42] and appeared essential for amyloid-induced neu-
rotoxicity [43]. On the other hand, elevation of Tau
levels seemed to have a general inhibitory effect on
anterograde trafficking and especially on vesicles car-
rying APP [44, 45]. This could alter APP trafficking
and amount to a possible decrease in APP processing
and A generation [46]. Finally, another relationship
between APP and Tau relates to GSK3 [47], an
enzyme able to both phosphorylate Tau and interact
with the -secretase cleavage of APP [48]. An anal-
ysis of our results suggested that FTD pathological
processes involved both amyloid and Tau pathways,
but in a different manner than in AD. The decrease of
sAPP, A38, and A40 levels in FTD suggested that
APP processing or availability was modified. This
might be a consequence of the pathology or linked to its
etiology. Longitudinal studies could help differentiate
these two possibilities. sAPP could also represent
a key element between tau- and amyloidopathies. The
specific fate of A38 may be related to its lower aggre-
gation tendency when compared to A40 or A42, as
well as its distinct production pathway by the  secre-
tase [49, 50], which might be modulated by sAPP
and/or Tau. Anyway, it is quite difficult to conclude on
the effect of these modifications since A38 has, to our
knowledge, no specific physiological effects.
Taken together, these data represent additional evi-
dence for the interrelationship between Tau and APP
biology. They could promote the development and
follow-up of optimal therapeutic strategies for different
types of dementia, as well as helping in their diagno-
sis as illustrated by our decisional algorithm based on
p-Tau and A38.
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